insights_auto
Why is IMM down 4.55%?
Dive Deeperchevron_right
IMM:ASX
Immutep Ltd
A$0.021
arrow_downward
-4.55%(-0.0010) 1D
Nov 3, 4:10:15 PM GMT+11 · AUD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IMM...
Open
A$0.02
High
A$0.02
Low
A$0.02
Mkt. cap
35.60M
Avg. vol.
8.48M
Volume
2.42M
52-wk high
A$0.47
52-wk low
A$0.02
EPS
-A$0.05
Shares outstanding
1.47B
No. of employees
19
Open
A$0.02
High
A$0.02
Low
A$0.02
Mkt. cap
35.60M
Avg. vol.
8.48M
Volume
2.42M
52-wk high
A$0.47
52-wk low
A$0.02
EPS
-A$0.05
Shares outstanding
1.47B
No. of employees
19
News stories
From web sources and news partners
FinancialContent
·
32 minutes ago
HNI (NYSE:HNI) reports sales below analyst estimates in Q3 2026 earnings
The Motley Fool
·
2 hours ago
The S&P 500's Record Profits Are Hiding a Problem Investors Haven't Seen Before
Crowdfund Insider
·
43 minutes ago
NYSE’s Tokenized Securities Platform to Offer On-Chain Shareholder Voting and Governance via Broadridge
Yahoo Finance
·
36 minutes ago
Upstart (NASDAQ:UPST) posts better-than-expected sales in Q3 2026, stock soars
Profile
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
About Immutep Ltd